Connect with us

Business

Breast Implants And Marijuana

Published

on

While marijuana is typically advised against before surgery, many doctors and surgeons are speaking out about its effects for after-care.

Breast implants are still a booming business. As one of the most popular surgeries, over 300,000+ women go under the knife annually. According to the American Society of Plastic Surgeons, Americans spent more than $16.5 billion on cosmetic surgery in 2018.  In Canada and the US over 300,000 woman have the procedure each year. So what about breast implants and marijuana?

With many instances of news covering breast implant illness, where individuals who have received breast implants describe symptoms like chest pain, fatigue, hair loss, and chronic pain, more patients are asking about the risks associated with getting implants or having them removed. And, with medical marijuana and CBD available in more states each year, considerations should be made when combining marijuana and the addition of implants or their removal.

Marijuana and Implant Surgery

Whether patients are undergoing surgery for a reduction or receiving implants, many doctors spoke to us about the importance of a candid conversation about marijuana use. Dr. Nathan Castillo, who practices out of Atlanta, GA,  shared that patients should, “refrain from smoking marijuana for at least 4-6 weeks before surgery.” Studies have found a link between marijuana use before surgery and a risk of vasodilation during surgery, the latter of which occurs when blood pressure falls due to blood vessels relaxing. Additionally, a 2018 study published in the journal Heliyon, found that consuming marijuana before surgery could complicate outcomes during and after the procedure. The study found that marijuana’s effects were most prevalent one hour after the start of the surgery and lasted anywhere from 2-4 hours. With an increase in both airway obstruction and anesthetic doses administered, the study found patients who consumed marijuana before surgery carried more risks than patients who abstained. However, while marijuana is typically advised against before surgery, many doctors and surgeons are speaking out about its effects for after-care. 

Cannabis’s role in follow-up care

Dr. Jonathan Kaplan specializes in plastic surgery and believes cannabis has an important role in the healing the body after a major medical procedure. He recently wrote marijuana not only offers an alternative to highly-addictive opioids and narcotics but decreasing pain after surgery while increasing a patient’s appetite which allows for more successful healing. He offered a comparison to marijuana’s effects before or after surgery to give insight to how marijuana operates inside the body—far differently than nicotine.

“Nicotine before or after surgery can constrict blood vessels and adversely affect wound healing. Marijuana, on the other hand, does not contain nicotine. Additionally, the risk of lung cancer seen with tobacco products doesn’t translate to marijuana either.” 

Dr. Kaplan isn’t alone in his findings. In fact, Dr. Vincent Maida at the University of Toronto authored a study that used cannabis-based medicines in a recent palliative care study. With a 90% success rate, healing wounds 27 out of 30 patients, he found that marijuana opened the door for the body to heal more quickly and successfully. Kaplan explained, “Topical medical cannabis has the potential to improve pain management in patients suffering from wounds of all classes,” offering possibility for cannabis to treat wounds from breast surgery or reduction in the upcoming years.

Whether patients are researching implants or their removal, studies and opinions seem to dictate that marijuana may heighten the body’s healing process after surgery. 

Source: https://thefreshtoast.com/cannabis/breast-implants-and-marijuana/

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News